Orphan Candidates for Clinical Development

 

AIRWAYS CANDIDATE. Orphan designated

 

Indications: CF (Orphan drug designated, EMA), COPD.

 

Broad spectrum anti-inflammatory properties and an excellent safety profile. It has demonstrated outstanding activity in human explant tissue.

 

Candidate for clinic development.

 

 

 

ONCOLOGY CANDIDATE. Orphan designated

 

Indications: pancreatic cancer (orphan drug designated, EMA and FDA), lung, gastric and liver cancers.

 

SYD003 is an immune modulator that breaks immune suppression around the tumor and allows both chemotherapy and immune cells to degrade the tumor.

 

Candidate for clinic development.

 

 

Synovo GmbH
Paul Ehrlich Str. 15
D-72076 Tübingen
Germany
Tel +49 (0) 7071 964325
Fax +49 (0) 7071 964326
Mail contact@synovo.com
 
© 2002-2014 Synovo GmbH